抗日本血吸虫单克隆抗体 NP30 抗独特型抗体嵌合 Fab 表达、鉴定及疗效观察。

Expression, characterization and therapeutic efficacy of chimeric Fab of anti-idiotypic antibody NP30 against Schistosoma japonicum.

机构信息

Key Lab of Antibody Technique of Ministry of Health, Nanjing Medical University, China.

出版信息

Acta Trop. 2011 May;118(2):159-64. doi: 10.1016/j.actatropica.2011.01.006. Epub 2011 Mar 3.

DOI:10.1016/j.actatropica.2011.01.006

Abstract

The murine monoclonal anti-idiotypic antibody NP30 is a promising therapeutic antibody against Schistosoma japonicum. However, the immunogenicity of murine NP30 limits its further study and application in humans. Here the chimeric Fab of NP30 (chFab-NP30) comprising the variable regions of murine NP30 and constant regions of human antibody was assembled. chFab-NP30 was expressed and purified as a soluble and functional protein. Administration of chFab-NP30 in vivo increased the survival rate, reduced egg burdens and ameliorated organ pathology of mice with acute schistosomiasis. Our study indicated that chFab-NP30 is a promising candidate to be used as a specific and efficient recombinant antibody against acute schistosomiasis japonica. Further studies on function mechanism of chFab-NP30 needs to be carried out in the future.

摘要

鼠源单克隆抗独特型抗体 NP30 是一种有前途的抗日本血吸虫病治疗性抗体。然而，鼠源 NP30 的免疫原性限制了其在人类中的进一步研究和应用。本研究构建了包含鼠源 NP30 可变区和人抗体恒定区的嵌合 Fab（chFab-NP30）。chFab-NP30 作为一种可溶性和功能性蛋白进行了表达和纯化。体内给予 chFab-NP30 可提高急性血吸虫病小鼠的存活率，降低虫卵负荷，改善器官病理。本研究表明，chFab-NP30 是一种有前途的候选药物，可作为一种针对日本血吸虫病的特异性、高效重组抗体。未来需要进一步研究 chFab-NP30 的作用机制。